Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Designer drugs 2015: assessment and management.

Michael F Weaver1, John A Hopper2, Erik W Gunderson3

  • 1The University of Texas Health Science Center at Houston, 1941 East Road, BBSB 1222, 77054, Houston, TX, USA. Michael.F.Weaver@uth.tmc.edu.

Addiction Science & Clinical Practice
|May 1, 2015
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial.

BMJ open·2026
Same author

A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol.

Contemporary clinical trials·2025
Same author

The Lookout Project: A Student-Run Mail-Based Overdose Response Kit Distribution Program Through Social Media During COVID-19.

Substance use & addiction journal·2024
Same author

E-cigarettes and Youth: The Known, the Unknown, and Implications for Stakeholders.

Journal of addiction medicine·2024
Same author

Contingency management plus acceptance and commitment therapy for initial cocaine abstinence: Results of a sequential multiple assignment randomized trial (SMART).

Drug and alcohol dependence·2024
Same author

Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study.

Journal of addiction medicine·2023

Designer drugs like synthetic cathinones and cannabinoids pose risks, causing severe psychiatric and medical issues. Treatment for designer drug use disorder remains challenging due to limited evidence.

Area of Science:

  • Forensic Chemistry
  • Toxicology
  • Psychiatry

Background:

  • Designer drugs, including substituted cathinones ("bath salts"), synthetic cannabinoids (SCs), and synthetic hallucinogens, are emerging rapidly.
  • Their availability and composition constantly change to circumvent legal controls and standard drug testing.
  • While young adults are primary users, military personnel are increasingly reporting use.

Purpose of the Study:

  • To highlight the evolving landscape of designer drug use.
  • To inform clinicians about the presentation and management of designer drug intoxication.
  • To underscore the challenges in treating designer drug use disorder.

Main Methods:

  • Review of current literature on designer drug trends and effects.

Related Experiment Videos

  • Analysis of clinical manifestations of acute designer drug toxicity.
  • Discussion of treatment approaches for acute intoxication and long-term use disorder.

    • Main Results:

    • Designer drugs are associated with severe acute toxicity, including psychiatric symptoms (anxiety, psychosis) and medical emergencies (tachycardia).
    • Multiple fatalities have been linked to various classes of designer drugs.
    • Clinicians must consider designer drugs in differential diagnoses for acute neuropsychiatric presentations.

    Conclusions:

    • Designer drug intoxication requires prompt supportive care focused on symptom management.
    • Long-term treatment for designer drug use disorder is complex and lacks robust evidence-based guidelines.
    • Awareness and vigilance are crucial for healthcare providers managing patients with potential designer drug exposure.